- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: New Clinical Trials, International Approvals for Samsung Bioepis
Samsung Bioepis has gained government clearance to begin a phase 3 clinical trial of its ranibizumab biosimilar in the Republic of Korea.
Samsung Bioepis has gained government clearance to begin a phase 3 clinical trial of its ranibizumab biosimilar in the Republic of Korea.
According to Korea Biomedical Review, the Korean Ministry of Food and Drug Safety (MFDS) has approved the company’s phase 3 clinical trial for SB11, a biosimilar product referencing Roche’s Lucentis, which is approved to treat neovascular age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. The multi-center domestic trial will comprise 140 patients who have AMD.
Samsung Bioepis is not alone in seeking a share of the market for Lucentis; US-based Pfenex and the German company Formycon are also developing biosimilar ranibizumab.
This week, Samsung Bioepis also gained MFDS approval to sell its adalimumab biosimilar, SB5, in the Republic of Korea. Samsung Bioepis gained a marketing authorization for the same drug, referenced on AbbVie’s blockbuster Humira, from the European Commission (EC) on August 24, 2017. The company plans to sell its biosimilar as Imraldi in the European Union.
News of Samsung Bioepis’ ranibizumab trial and adalimumab approval follow last week’s progress for its biosimilar trastuzumab, SB3, referenced on Herceptin. On Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion of the drug.
On EC clearance, Samsung Bioepis plans to market the drug under the name Ontruzant. In order to ensure a reliable supply of the trastuzumab treatment, the company plans to partner with multiple contracting organizations to carry out production of Ontruzant, a Samsung representative said.
Meanwhile, the biosimilar developer fended off rumors of a split with its marketing and distribution partner, MSD, in the Korean market. The Investor says that representatives from Samsung Bioepis today denied reports that a drug licensing agreement with MSD for Brenzys (a biosimilar etanercept, referenced on Enbrel) and Renflexis (a biosimilar infliximab, referenced on Remicade) had terminated after disappointing sales of the 2 biosimilars. According to The Investor, the cost savings provided by biosimilar therapies in the Korean marketplace typically do not exceed 10%, and have not produced rapid sales.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
